Hongjun Li1, Hui Qiao, Hongjie Lu, Changqi Liu. 1. Department of Anesthesiology, People's Hospital of Zhengzhou, Zhengzhou, 450000, China, lihongjunli1111@163.com.
Abstract
OBJECTIVE: We wished to evaluate the effect of sufentanil lipid nanoparticles on peripheral analgesia of inflammatory pain model rats. METHODS: Ninety SD rats were randomly divided into an inflammatory model group (group A, n = 54) and a blank control group (group B, n = 36). Group A was further divided into the sufentanil lipid nanoparticles group (group A1, n = 18), the sufentanil group (group A2, n = 18), and the inflammatory pain model group (group A3, n = 18); group B was divided into the sufentanil lipid nanoparticles group (group B1, n = 18) and the sufentanil group (group B2, n = 18). Rats of group A were given a formalin injection in the foot to produce the inflammatory pain model. Group B rats were given a normal saline foot injection of the same dosage. Then, groups A1 and B1 were given sufentanil lipid nanoparticles (0.82 μg/kg) treatment. Groups A2 and B2 were given sufentanil of the same dosage, and group A3 were given normal saline. Pain scores of Group A rats were recorded and analyzed. The ELISA method was adopted to determine drug concentration in rat brain, plasma, and the inflammatory pain/subcutaneous area. RESULTS: Pain scores of rats in group A3 were always higher than those in groups A1 and A2, and the pain scores of group A2 were higher than in group A1 0-30 min after administration (P < 0.05). The brain drug concentration in groups A2 and B1 fluctuated over time; the brain drug concentrations of groups A2 and B2 were respectively higher than those of groups A1 and B1 (P < 0.05). There was no significant difference between the plasma drug concentrations of different groups at the same time point (P > 0.05); however, there was a notable difference within each group at different time points (P < 0.05), and the drug concentration of the inflammatory tissues in group A1 changed significantly over time (P < 0.05). Thirty minutes after administration, drug concentration in the inflammatory site of group A1 was higher than that of groups A2, B1, and B2 (P < 0.05). CONCLUSION: Sufentanil lipid nanoparticles had a comparatively weak effect on the central nervous system because of their features such as large particle size and targeted and controlled release. They have shown a remarkable analgesic effect in the peripheral inflammatory pain areas.
OBJECTIVE: We wished to evaluate the effect of sufentanil lipid nanoparticles on peripheral analgesia of inflammatory pain model rats. METHODS: Ninety SD rats were randomly divided into an inflammatory model group (group A, n = 54) and a blank control group (group B, n = 36). Group A was further divided into the sufentanil lipid nanoparticles group (group A1, n = 18), the sufentanil group (group A2, n = 18), and the inflammatory pain model group (group A3, n = 18); group B was divided into the sufentanil lipid nanoparticles group (group B1, n = 18) and the sufentanil group (group B2, n = 18). Rats of group A were given a formalin injection in the foot to produce the inflammatory pain model. Group B rats were given a normal saline foot injection of the same dosage. Then, groups A1 and B1 were given sufentanil lipid nanoparticles (0.82 μg/kg) treatment. Groups A2 and B2 were given sufentanil of the same dosage, and group A3 were given normal saline. Pain scores of Group A rats were recorded and analyzed. The ELISA method was adopted to determine drug concentration in rat brain, plasma, and the inflammatory pain/subcutaneous area. RESULTS:Pain scores of rats in group A3 were always higher than those in groups A1 and A2, and the pain scores of group A2 were higher than in group A1 0-30 min after administration (P < 0.05). The brain drug concentration in groups A2 and B1 fluctuated over time; the brain drug concentrations of groups A2 and B2 were respectively higher than those of groups A1 and B1 (P < 0.05). There was no significant difference between the plasma drug concentrations of different groups at the same time point (P > 0.05); however, there was a notable difference within each group at different time points (P < 0.05), and the drug concentration of the inflammatory tissues in group A1 changed significantly over time (P < 0.05). Thirty minutes after administration, drug concentration in the inflammatory site of group A1 was higher than that of groups A2, B1, and B2 (P < 0.05). CONCLUSION:Sufentanil lipid nanoparticles had a comparatively weak effect on the central nervous system because of their features such as large particle size and targeted and controlled release. They have shown a remarkable analgesic effect in the peripheral inflammatory pain areas.
Authors: Daniele R de Araújo; Deyse C da Silva; Raquel M Barbosa; Michelle Franz-Montan; Cíntia M S Cereda; Cristina Padula; Patrizia Santi; Eneida de Paula Journal: Expert Opin Drug Deliv Date: 2013-08-13 Impact factor: 6.648